TARE FOR HEPATOCELLULAR CARCINOMA:
INDICATIONS, EVIDENCE, AND PATIENT SELECTION
A complete clinical guide to Y-90 radioembolization in HCC โ when it is used, what the trial evidence shows, who is the best candidate, and how dosimetry determines outcomes across the BCLC staging spectrum.
analyticsAt a Glance
- check_circleTARE is applicable across BCLC stages A through C โ the broadest locoregional application in HCC
- check_circlePhase III SARAH and SIRveNIB trials showed TARE is non-inferior to sorafenib with significantly better tolerability
- check_circlePersonalised dosimetry targeting >200 Gy achieves complete pathological response in 25โ35% of HCC patients
- check_circleCancerFax coordinates TARE for HCC at specialist interventional oncology centres in China and India
The Role of TARE Across the HCC Treatment Spectrum
TARE is uniquely versatile in HCC management โ applicable from early-stage disease (where it can serve as a curative-intent locoregional ablative strategy) through intermediate and advanced stages (where it provides locoregional disease control alongside or instead of systemic therapy). No other locoregional treatment spans this staging range as effectively.
โTARE is the only locoregional therapy in HCC that can meaningfully serve curative, bridging, downstaging, and palliative intents depending on how it is applied.โ
Curative Intent โ Radiation Segmentectomy (BCLC A)
For small (<3 cm), solitary HCC in a well-defined liver segment, high-dose TARE (>200 Gy to the tumour-bearing segment) achieves complete pathological response rates of 25โ35% โ comparable to thermal ablation, with the advantage of treating tumours adjacent to major vessels where RFA is technically challenging.
Bridging and Downstaging โ Transplant Context (BCLC AโB)
For patients awaiting liver transplantation, TARE prevents tumour progression beyond Milan criteria during the waiting period (bridging) or reduces tumour burden to within transplant criteria (downstaging). TARE is particularly valued in this setting for its low risk of arterial damage that could complicate subsequent hepatectomy.
Intermediate-Stage Disease (BCLC B)
For multinodular BCLC B HCC not amenable to curative treatment, TARE provides lobar or bilobar disease control โ with Phase III evidence demonstrating tolerability and quality-of-life superiority over sorafenib, and retrospective series showing durable response in high-dose treated patients.
Advanced-Stage Disease (BCLC C)
TARE is one of the few locoregional therapies that can be used safely in patients with portal vein tumour thrombus โ the defining feature of BCLC C. Its ability to treat the liver in the context of limited portal flow distinguishes it from TACE, which carries higher ischaemic risk in PVT.
Phase III Trial Evidence: SARAH and SIRveNIB
Two Phase III randomised controlled trials have directly compared TARE against sorafenib in advanced HCC โ the first head-to-head evidence for TARE in this setting.
SARAH Trial: TheraSphere vs Sorafenib (Advanced HCC)
TheraSphere Y-90 vs sorafenib in advanced/locally advanced HCC. Primary endpoint: OS. Source: Vilgrain et al., Lancet Oncology 2017.
- Median OS: TheraSphere8.0 months
- Median OS: sorafenib9.9 months
- Grade 3โ4 AE rate: TheraSphere28%
- Grade 3โ4 AE rate: sorafenib52%
SIRveNIB Trial: SIR-Spheres vs Sorafenib (Advanced HCC, Asia-Pacific)
SIR-Spheres Y-90 vs sorafenib in advanced HCC in Asia-Pacific patients (predominantly HBV-related). Source: Chow et al., JCO 2018.
- Median OS: SIR-Spheres8.8 months
- Median OS: sorafenib10.0 months
- ORR (tumour response): SIR-Spheres16.5%
- ORR: sorafenib1.7%
TARE Patient Selection in HCC โ Eligibility Reference
A structured eligibility reference for TARE in HCC, organised by clinical factor. All criteria should be assessed in an multidisciplinary tumour board discussion.
| Selection Factor | Favourable for TARE | Requires Assessment | Contraindicated |
|---|---|---|---|
| BCLC stage | A, B, C (selected) | BCLC D (very poor prognosis) | BCLC D with advanced liver failure |
| Child-Pugh score | Child-Pugh A | Child-Pugh B7โ8 | Child-Pugh C / B9+ |
| Portal vein status | Patent or branch PVT | Main trunk PVT | Bilateral PVTT with no portal flow |
| Lung shunt fraction | < 10% | 10โ20% (activity reduction) | > 20% |
| Bilirubin | < 2 mg/dL | 2โ3 mg/dL | > 3 mg/dL |
| ECOG performance status | 0โ1 | 2 | 3โ4 |
| Prior TACE | TACE failure / intolerance | Multiple prior TACE cycles | N/A โ TARE can be used post-TACE |
| Tumour type | HCC (confirmed histology or imaging per LI-RADS 5) | Combined HCC-ICC | Extensive infiltrative HCC with massive liver replacement |
When TARE Is Preferred Over TACE for HCC
TACE remains the BCLC B standard, but there are specific clinical contexts where TARE is preferred or necessary.
Prefer TARE
- Portal vein tumour thrombus (PVTT)TARE can treat the liver safely when portal blood flow is compromised by tumour thrombus โ a setting where TACE embolization carries higher ischaemic risk.
- Bilobar multifocal disease requiring whole-liver treatmentSequential lobar TARE (right lobe then left lobe) allows whole-liver treatment with lower toxicity than bilobar TACE in a single session.
- TACE failure or intolerancePatients who have progressed on or cannot tolerate TACE are the primary TARE referral population in many centres โ TARE offers an alternative mechanism without requiring the embolic component.
- Radiation segmentectomy intentWhen high-dose ablative strategy is intended (>200 Gy to a defined liver segment), TARE is the only platform capable of delivering this dose โ TACE cannot achieve equivalent radiation dosing.
Prefer TACE
- BCLC B multinodular HCC โ standard of careTACE has the established evidence base and guideline backing for intermediate HCC โ the default choice at most centres for new BCLC B diagnoses.
- Child-Pugh B patients where embolic tumour control is priorityWhen tumour devascularisation is the primary therapeutic goal and liver function is marginal, cTACE or DEB-TACE may deliver dual embolic and chemotherapy benefit.
- Centres without Y-90 supply or nuclear medicine infrastructureTACE requires only standard IR equipment โ TARE requires Y-90 supply chain, nuclear medicine imaging, and radiation safety infrastructure unavailable at most facilities.
TARE for HCC โ Key Numbers
The most clinically important quantitative benchmarks for TARE in hepatocellular carcinoma.
- ~25โ35%Complete pathological response rate with high-dose TARE (>200 Gy) for HCCAchievable with partition model dosimetry โ a complete response rate comparable to thermal ablation, accessible in tumours where ablation is technically impossible.
- HR ~1.0Overall survival hazard ratio vs sorafenib (SARAH and SIRveNIB pooled)TARE is non-inferior to sorafenib in OS across both Phase III trials โ with dramatically better tolerability and fewer grade 3โ4 adverse events.
- BCLC AโCBCLC stages where TARE has clinical applicationNo other single locoregional therapy spans the full early-to-advanced HCC staging range โ TARE's versatility is a defining clinical advantage.
More from the TARE / Y-90 Resource Library
Explore related guides โ from radiation segmentectomy and radiation lobectomy to TARE for portal vein thrombosis and colorectal liver metastases.
Frequently Asked Questions: TARE for HCC
Can TARE be used alongside systemic therapy (sorafenib, lenvatinib, or immunotherapy)?
TARE combined with systemic therapy is one of the most actively investigated areas in HCC. Retrospective data and early-phase trials suggest that combining TARE with atezolizumab + bevacizumab or with PD-1 inhibitors may produce synergistic anti-tumour effects โ TARE-induced immunogenic cell death may enhance immune checkpoint inhibitor activity. Formal Phase III trials are ongoing. In current clinical practice, combined TARE + systemic therapy is offered at specialist centres on a case-by-case basis or within clinical trials. CancerFax can identify centres in China and India currently running TARE + IO combination protocols.
If I have had prior TACE, can I still receive TARE?
Yes โ in fact, TACE failure or progression is one of the most common clinical situations prompting TARE referral. Prior TACE does not preclude TARE, provided liver function has recovered, the arterial anatomy is still favourable (multiple TACE sessions can cause hepatic artery damage or occlusion), and the lung shunt fraction remains acceptable at mapping. The interventional radiologist will carefully assess hepatic artery patency and liver reserve before proceeding, particularly if more than three TACE cycles have been performed.
My HCC was diagnosed as unresectable. Can TARE make it resectable?
Possibly โ this is the downstaging application of TARE. For carefully selected patients, TARE to the tumour-bearing liver lobe can achieve sufficient tumour response to bring a patient within resectability criteria. TARE is also used as radiation lobectomy โ delivering high dose to one lobe to induce its atrophy and drive compensatory hypertrophy of the future liver remnant (FLR), improving surgical safety before planned hepatectomy. CancerFax can review your imaging and liver function data to assess whether downstaging or radiation lobectomy might be applicable to your case.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination โ travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Is TARE an Option for Your Liver Cancer?
CancerFax reviews your HCC records โ BCLC stage, portal vein status, Child-Pugh score, AFP, and prior treatment history โ to assess TARE eligibility and coordinates access at specialist Y-90 centres.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist and interventional radiologist before making treatment decisions.